Airoldi M, Cortesina G, Giordano C, Pedani F, Cavalot A, Marcato P, Beatrice F, Bumma C
Department of Medical Oncology, S. Giovanni Antica Sede Hospital, Turin, Italy.
Acta Otorhinolaryngol Ital. 2003 Oct;23(5):368-76.
Surgery is the treatment of choice for major and minor salivary gland malignancies. Herein, the role of radiation and medical treatment in the multidisciplinary management of salivary gland tumours is discussed. Neutron irradiation and hyperfractionated external beam mega voltage irradiation improve local control. Combination of three dimensional conformal radiotherapy and intensive-modulated radiation therapy provide better local tumour delineation, better field design to encompass the tumour allowing dose escalation to target while sparing the surrounding normal tissue. Cisplatin-based chemotherapy provides a response rate > or = 45%, in a palliative setting. Concomitant chemo-radiotherapy could improve local control. Recent studies evaluated the expression of molecular targets in salivary gland carcinomas (c-kit = 53-90%, EGFR = 25-85%, c-erb-B2 = 11-58%, p53 = 11-67%, H ras = 18%); these targets are very important since new targeted drugs are now available. Anti-androgen therapy might have a role in the management of patients with ductal carcinoma. These new targeted drugs could be integrated with chemotherapy and radiotherapy in the treatment of locally advanced/metastatic salivary gland malignancies.
手术是治疗大、小唾液腺恶性肿瘤的首选方法。本文讨论了放疗和药物治疗在唾液腺肿瘤多学科管理中的作用。中子照射和超分割外照射兆伏级放疗可改善局部控制。三维适形放疗和调强放疗相结合能更好地勾勒局部肿瘤,优化射野设计以涵盖肿瘤,从而在保护周围正常组织的同时提高靶区剂量。在姑息治疗中,以顺铂为基础的化疗有效率≥45%。同步放化疗可改善局部控制。近期研究评估了唾液腺癌中分子靶点的表达情况(c-kit = 53 - 90%,EGFR = 25 - 85%,c-erb-B2 = 11 - 58%,p53 = 11 - 67%,H ras = 18%);由于现在有了新的靶向药物,这些靶点非常重要。抗雄激素治疗可能在导管癌患者的管理中发挥作用。这些新的靶向药物可与化疗和放疗联合用于治疗局部晚期/转移性唾液腺恶性肿瘤。